An acute T-lymphoblastic leukemia occurring in adults.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation for T-cell adult acute lymphocytic leukemia is limited due to its relatively low prevalence and the complexity of its clinical features. The rarity of the condition means that systematic studies are sparse, and the lack of identified genetic factors further complicates characterization. As research continues, there is hope that more information will become available, enhancing understanding and treatment options.
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in acute leukemias, particularly T-cell types. Engaging with clinical trial coordinators can also provide access to cutting-edge treatments. You may find valuable resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on ongoing research and clinical trials. While no specific patient organizations are identified, participating in clinical trials may provide additional support and information.
Currently, there are three FDA-approved orphan drugs for T-cell adult acute lymphocytic leukemia: blinatumomab, Pegaspargase, and revumenib. Additionally, several drugs are designated for development, including a humanized anti-CD3/CD19 bispecific antibody and Autologous anti-CD19 CAR-T cells. There are 137 active clinical trials exploring various treatment options. For more information, you can search for ongoing trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=T-cell%20adult%20acute%20lymphocytic%20leukemia.
Actionable guidance for navigating care for T-cell adult acute lymphocytic leukemia
To navigate your care effectively, consider seeking a hematologist or oncologist with expertise in acute leukemias, particularly T-cell types. Engaging with clinical trial coordinators can also provide access to cutting-edge treatments. You may find valuable resources through the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers information on ongoing research and clinical trials. While no specific patient organizations are identified, participating in clinical trials may provide additional support and information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.